Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, today announced that dosing is underway for the first cohort of patients in its Phase ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

Patients with RA who use abatacept mount little humoral or cell-mediated responses to the recombinant zoster vaccine, with more injection-site reactions but similar RA flare rates compared with ...

The FDA has previously granted fast track designation to aglatimagene plus valacyclovir in combination with ICI therapy for ...